Michael P DiGiovanna, MD, PhD

Associate Professor of Medicine (Medical Oncology) and of Pharmacology

Physician Biography

Dr. DiGiovanna is a native of Long Island, NY, who graduated from Cornell University in 1984 with a B.A. and a double major in the fields of biochemistry and music. He attended Yale University from 1984 through 1990 where he was earned the MD and PhD degrees, with his PhD in Pharmacology. He continued his post-graduate training at Yale, performing internship and residency in Internal Medicine, a research post-doctoral fellowship, and a clinical fellowship in Medical Oncology. He is currently an attending physician in Medical Oncology and Associate Professor of Medicine (Oncology) and Pharmacology at Yale University. His clinical specialty is breast cancer and he conducts both clinical and laboratory-based research. His translational laboratory research is focused on signal transduction in breast cancer. He also has a leadership role in education at the Yale School of Medicine, including current roles as Director of Pharmacology Curriculum and Director of Modules (clinical pathophysiology courses).

Clinical Interests

  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Breast Cancer Program

Medical Oncology: Subset Medical Oncology Faculty

Yale Medical Group

Board Certifications

  • Medical Oncology AB of Internal Medicine (1997)

Clinical Trials

Conditions Study Title
Breast - Female A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less (SWOG S1007) (CIRB)
Breast Cancer MAP-IT
Breast - Female, Breast - Male Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (S1207)
Breast - Female, Breast - Male Randomized Phase II trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations
Anus, Bladder, Breast - Female, Breast - Male, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Liver, Lung, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CANCER
Breast - Female SINGLE ARM, NEOADJUVANT, PHASE II TRIAL OF PERTUZUMAB AND TRASTUZUMAB ADMINISTERED CONCOMITANTLY WITH WEEKLY PACLITAXEL AND FEC FOR CLINICAL STAGE I-III HER2-POSITIVE BREAST CANCER
Breast - Female, Breast - Male A Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes following Preoperative Therapy (NSABP B50/Katherine Study)
Breast - Female A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer
Breast - Female, Breast - Male A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)
Breast - Female A neoadjuvant phase II trial of aromatase inhibitors in combination with everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancers with low and intermediate risk (less than or equal to 25) Oncotype Dx Recurrence Scores
Breast - Female, Breast - Male A Phase 2, randomized, open-label, multicenter, safety and efficacy study of oral lucitanib in patients with FGF aberrant metastatic breast cancer
Breast - Female, Breast - Male A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician's Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with germline BRCA1/2 Mutations (OlympiAD)
Breast - Female, Breast - Male A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician¡¦s Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer
Breast - Female A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Breast - Female, Breast - Male B55: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

Edit this profile

Contact Info

Michael P DiGiovanna, MD, PhD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste NP - 1

New Haven, CT 06510
Mailing Address
PO Box 208032
300 George Street

New Haven, CT 06520-8032